TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06990698: A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP008 in Subjects With Advanced Solid Tumors

Sponsor: Zhuhai Fapon Biopharma Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,728,336

Rescue Site Savings

+$5,089,392

Unlock Full NCT06990698 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06990698 Rescue Dossier →